Table 2. Variables associated with... | American Society of Hematology

Table 2.

Variables associated with outcomes after intermediate intensity dCBT

Variables	Value	n	Univariate analysis
Variables	Value	n	HR (95% CI)	P
Neutrophil engraftment: dCBT recipients only (n = 47)
TNC cell dose per kilogram	<2.6 × 10⁷	21	Reference	.286
TNC cell dose per kilogram	≥2.6 × 10⁷	26	1.38 (0.76-2.51)	.286
TNC cell dose per kilogram	Continuous	47	3.81 (1.31-11.01)	.014
CD34⁺ cell dose per kilogram	<1.4 × 10⁵	21	Reference	.001
CD34⁺ cell dose per kilogram	≥1.4 × 10⁵	26	2.77 (1.51-5.09)	.001
CD34⁺ cell dose per kilogram	Continuous	47	2.53 (1.55-4.12)	<.001
Donor-recipient 8-allele HLA-match	3-4/8	20	Reference
	5/8	16	1.11 (0.56-2.19)	.764
	6-7/8	11	0.87 (0.41-1.86)	.723
Nonsignificant variables included engrafting unit CD3⁺ cell dose. Infused CD34⁺ dose represented viable cells. Haploidentical CD34⁺cell recipients were excluded due to the transient engraftment of these cells in some patients.
Grade III-IV aGVHD (n = 90)
Nonsignificant variables included recipient age, sex, ancestry (European vs non-European), CMV serostatus, addition of haploidentical CD34⁺ cells, HCT-CI, rDRI and engrafting unit TNC, CD34⁺ and CD3⁺ cell doses, and 8-allele HLA match.
TRM (n = 90)
Age, y	<50	48	Reference	.03
Age, y	≥50	42	4.19 (1.15-15.22)	.03
Age, y	Continuous	90	1.1 (1.0-1.20)	.016
HCT-CI	0-2	58	Reference	.79
HCT-CI	3-8	32	1.16 (0.38-3.56)	.79
CD34⁺ cell dose per kilogram	<1.4 × 10⁵	45	Reference	.145
CD34⁺ cell dose per kilogram	≥1.4 × 10⁵	45	0.42 (0.13-1.35)	.145
CD34⁺ cell dose per kilogram	Continuous	90	0.30 (0.11-0.82)	.017
Nonsignificant variables included recipient sex, ancestry (European vs non-European), CMV serostatus, addition of haploidentical CD34⁺ cells, rDRI and engrafting unit TNC, CD3⁺ cell doses, and 8-allele HLA-match.
Relapse (n = 90)
Age, y	<50	48	Reference	.261
Age, y	≥50	42	0.46 (0.12-1.79)	.261
Age, y	Continuous	90	0.97 (0.92-1.03)	.330
rDRI	Low-intermediate	68	Reference	.313
rDRI	High-very high	22	1.92 (0.54-6.84)	.313
Nonsignificant variables included recipient xer, ancestry (European vs non-European), CMV serostatus, addition of haploidentical CD34⁺ cells, HCT-CI and engrafting unit TNC and CD3⁺ cell doses, and 8-allele HLA match.
OS (n = 90)
Age, y	<50	48	Reference	.057
Age, y	≥50	42	2.79 (0.97-8.03)	.057
Age, y	Continuous	90	1.09 (1.02-1.16)	.013
HCT-CI	0-2	58	Reference	.446
HCT-CI	3-8	32	1.47 (0.55-3.94)	.446
CD34⁺ cell dose per kilogram	Continuous	90	0.38 (0.14-0.99)	.047
Other nonsignificant variables included recipient sex, ancestry (European vs non-European), CMV serostatus, addition of haploidentical CD34⁺ cells, rDRI and engrafting unit TNC and CD3⁺ cell doses, and 8-allele HLA match.
PFS (n = 90)
Age, y	<50	48	Reference	.364
Age, y	≥50	42	1.47 (0.64-3.35)	.364
Age, y	Continuous	90	1.03 (0.98-1.07)	.218
HCT-CI	0-2	58	Reference	.439
HCT-CI	3-8	32	1.39 (0.61-3.16)	.439
CD34⁺ cell dose per kilogram	Continuous	90	0.57(0.26-1.27)	.171
Other nonsignificant variables included recipient sex, ancestry (European vs non-European), CMV serostatus, addition of haploidentical CD34⁺ cells, rDRI and engrafting unit TNC and CD3⁺ cell doses, and 8-allele HLA match.

Variables	Value	n	Univariate analysis
Variables	Value	n	HR (95% CI)	P
Neutrophil engraftment: dCBT recipients only (n = 47)
TNC cell dose per kilogram	<2.6 × 10⁷	21	Reference	.286
TNC cell dose per kilogram	≥2.6 × 10⁷	26	1.38 (0.76-2.51)	.286
TNC cell dose per kilogram	Continuous	47	3.81 (1.31-11.01)	.014
CD34⁺ cell dose per kilogram	<1.4 × 10⁵	21	Reference	.001
CD34⁺ cell dose per kilogram	≥1.4 × 10⁵	26	2.77 (1.51-5.09)	.001
CD34⁺ cell dose per kilogram	Continuous	47	2.53 (1.55-4.12)	<.001
Donor-recipient 8-allele HLA-match	3-4/8	20	Reference
	5/8	16	1.11 (0.56-2.19)	.764
	6-7/8	11	0.87 (0.41-1.86)	.723
Nonsignificant variables included engrafting unit CD3⁺ cell dose. Infused CD34⁺ dose represented viable cells. Haploidentical CD34⁺cell recipients were excluded due to the transient engraftment of these cells in some patients.
Grade III-IV aGVHD (n = 90)
Nonsignificant variables included recipient age, sex, ancestry (European vs non-European), CMV serostatus, addition of haploidentical CD34⁺ cells, HCT-CI, rDRI and engrafting unit TNC, CD34⁺ and CD3⁺ cell doses, and 8-allele HLA match.
TRM (n = 90)
Age, y	<50	48	Reference	.03
Age, y	≥50	42	4.19 (1.15-15.22)	.03
Age, y	Continuous	90	1.1 (1.0-1.20)	.016
HCT-CI	0-2	58	Reference	.79
HCT-CI	3-8	32	1.16 (0.38-3.56)	.79
CD34⁺ cell dose per kilogram	<1.4 × 10⁵	45	Reference	.145
CD34⁺ cell dose per kilogram	≥1.4 × 10⁵	45	0.42 (0.13-1.35)	.145
CD34⁺ cell dose per kilogram	Continuous	90	0.30 (0.11-0.82)	.017
Nonsignificant variables included recipient sex, ancestry (European vs non-European), CMV serostatus, addition of haploidentical CD34⁺ cells, rDRI and engrafting unit TNC, CD3⁺ cell doses, and 8-allele HLA-match.
Relapse (n = 90)
Age, y	<50	48	Reference	.261
Age, y	≥50	42	0.46 (0.12-1.79)	.261
Age, y	Continuous	90	0.97 (0.92-1.03)	.330
rDRI	Low-intermediate	68	Reference	.313
rDRI	High-very high	22	1.92 (0.54-6.84)	.313
Nonsignificant variables included recipient xer, ancestry (European vs non-European), CMV serostatus, addition of haploidentical CD34⁺ cells, HCT-CI and engrafting unit TNC and CD3⁺ cell doses, and 8-allele HLA match.
OS (n = 90)
Age, y	<50	48	Reference	.057
Age, y	≥50	42	2.79 (0.97-8.03)	.057
Age, y	Continuous	90	1.09 (1.02-1.16)	.013
HCT-CI	0-2	58	Reference	.446
HCT-CI	3-8	32	1.47 (0.55-3.94)	.446
CD34⁺ cell dose per kilogram	Continuous	90	0.38 (0.14-0.99)	.047
Other nonsignificant variables included recipient sex, ancestry (European vs non-European), CMV serostatus, addition of haploidentical CD34⁺ cells, rDRI and engrafting unit TNC and CD3⁺ cell doses, and 8-allele HLA match.
PFS (n = 90)
Age, y	<50	48	Reference	.364
Age, y	≥50	42	1.47 (0.64-3.35)	.364
Age, y	Continuous	90	1.03 (0.98-1.07)	.218
HCT-CI	0-2	58	Reference	.439
HCT-CI	3-8	32	1.39 (0.61-3.16)	.439
CD34⁺ cell dose per kilogram	Continuous	90	0.57(0.26-1.27)	.171
Other nonsignificant variables included recipient sex, ancestry (European vs non-European), CMV serostatus, addition of haploidentical CD34⁺ cells, rDRI and engrafting unit TNC and CD3⁺ cell doses, and 8-allele HLA match.

Infused cell dose and HLA-match variables are those of the engrafting unit. Infused TNC, infused viable CD34⁺, and infused viable CD3⁺ cell doses were naturally log transformed when examined as continuous variables because of skewness. Values of P < .05 are in bold.

[ViewLarge]

This Feature Is Available To Subscribers Only